Vanc Pharmaceuticals - 500 Beiträge pro Seite
eröffnet am 22.02.15 15:43:04 von
neuester Beitrag 21.01.16 13:30:54 von
neuester Beitrag 21.01.16 13:30:54 von
Beiträge: 46
ID: 1.208.099
ID: 1.208.099
Aufrufe heute: 0
Gesamt: 38.452
Gesamt: 38.452
Aktive User: 0
ISIN: CA0545211090 · WKN: A2N8S1 · Symbol: 8VP1
0,0990
EUR
+1,54 %
+0,0015 EUR
Letzter Kurs 15.04.24 Tradegate
Neuigkeiten
04.04.24 · globenewswire  |
15.09.23 · globenewswire |
30.08.23 · globenewswire |
08.08.23 · globenewswire |
03.08.23 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0400 | +48,57 | |
| 12,810 | +39,69 | |
| 0,5400 | +38,46 | |
| 27,80 | +32,38 | |
| 31,00 | +24,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6610 | -24,02 | |
| 0,7350 | -31,31 | |
| 28,18 | -32,62 | |
| 0,5660 | -40,42 | |
| 2,8100 | -48,72 |
Feedback
Hallo,
seit einigen Wochen beobachte ich die Aktie der Vanc Pharmaceutical.
Am Donnerstag nun began der Ausbruch nach oben von ca. 17/18 cent auf aktuell 28,5 cent.
Grund war folgende news am Freitag:
http://www.stockhouse.com/news/press-releases/2015/02/20/van…
"VANC Pharmaceuticals Announces Supplier Letter of Intent With a Western Canadian Pharmacy Chain
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 20, 2015) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has signed a Letter of Intent (LOI) with a Western Canada based multi-chain pharmacy, to become a preferred supplier of generic drugs and over-the-counter (OTC) products.
"This is a major step in our commercialization efforts and we are excited to have formed a partnership with an established pharmacy chain. We are ramping up our sales and marketing efforts as we prepare to take delivery of our first inventory orders in early Q2-2015," said Arun Nayyar, CEO of Vanc.
Additional updates on the Company's commercialization plans will be provided this quarter.
On behalf of:
VANC Pharmaceuticals Inc.
Arun Nayyar, President and CEO
..."
seit einigen Wochen beobachte ich die Aktie der Vanc Pharmaceutical.
Am Donnerstag nun began der Ausbruch nach oben von ca. 17/18 cent auf aktuell 28,5 cent.
Grund war folgende news am Freitag:
http://www.stockhouse.com/news/press-releases/2015/02/20/van…
"VANC Pharmaceuticals Announces Supplier Letter of Intent With a Western Canadian Pharmacy Chain
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 20, 2015) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has signed a Letter of Intent (LOI) with a Western Canada based multi-chain pharmacy, to become a preferred supplier of generic drugs and over-the-counter (OTC) products.
"This is a major step in our commercialization efforts and we are excited to have formed a partnership with an established pharmacy chain. We are ramping up our sales and marketing efforts as we prepare to take delivery of our first inventory orders in early Q2-2015," said Arun Nayyar, CEO of Vanc.
Additional updates on the Company's commercialization plans will be provided this quarter.
On behalf of:
VANC Pharmaceuticals Inc.
Arun Nayyar, President and CEO
..."
Prognose: RAPIDER weiterer Kursanstieg - ein buy and hold no brainer an der TSX-V ... das sagt schon alles meine ich ...
Gruß, praesens
Gruß, praesens
Gelistet an der TSX-V.
WKN: A119PH
ISIN: CA92143R1055
Symbol: V.NPH
WKN: A119PH
ISIN: CA92143R1055
Symbol: V.NPH
Ausgegebene Aktien: ca. 44 mio
fully diluted ca. 64 mio
Quelle: stockhouse
marketcap. aktuell ca. 12,5 mio $
homepage: http://www.vancpharm.com/
Kontakt:
a)
Richmond Office
Head Offices:
Suite 210
2639 Viking Way
Richmond, B.C. V6V 3B7
Office number: 604 247 2639
Fax number: 604 303 9170
E-mail: info@vancpharm.com
b)
Vancouver Office
Registered Corporate Offices:
Suite 615
800 West Pender Street
Vancouver, B.C. V6C 2V6
Phone number: 604 687 2038
Fax number: 604 687 3141
E-mail: info@vancpharm.com
fully diluted ca. 64 mio
Quelle: stockhouse
marketcap. aktuell ca. 12,5 mio $
homepage: http://www.vancpharm.com/
Kontakt:
a)
Richmond Office
Head Offices:
Suite 210
2639 Viking Way
Richmond, B.C. V6V 3B7
Office number: 604 247 2639
Fax number: 604 303 9170
E-mail: info@vancpharm.com
b)
Vancouver Office
Registered Corporate Offices:
Suite 615
800 West Pender Street
Vancouver, B.C. V6C 2V6
Phone number: 604 687 2038
Fax number: 604 687 3141
E-mail: info@vancpharm.com
Alleine am Freitag wurden 25 % !! der ausgegebenen Aktien gehandelt.
Das Kursplus dabei: 32 %
Das Kursplus dabei: 32 %
Trading Spotlight
Auflistung der vergangenen news u.a. hier:
http://www.stockhouse.com/companies/news/v.nph/vanc-pharmace…
Alleine die Überschriften zu den einzelnen news sind schon aussagekräftig ...
Gruß, praesens
http://www.stockhouse.com/companies/news/v.nph/vanc-pharmace…
Alleine die Überschriften zu den einzelnen news sind schon aussagekräftig ...
Gruß, praesens
DER news flow bzw. die dahinter steckende Arbeit bzw. das Erreichen der Ziele - nur zu möglich mit einem Top-Management:
http://www.vancpharm.com/management/
http://www.vancpharm.com/management/
Eine sehr gute Übersicht findet sich zu Beginn des investorshub boards:
http://investorshub.advfn.com/Vanc-Pharmaceuticals-Inc-TSXV-…
http://investorshub.advfn.com/Vanc-Pharmaceuticals-Inc-TSXV-…
Chart:
Antwort auf Beitrag Nr.: 49.141.664 von praesens am 22.02.15 16:04:06
auf iHub findet man finde ich generell, öfter, ganz gute Übersichten zu den Firmen
da sehen so einige Recherchen dagegen blass aus
Zitat von praesens: Eine sehr gute Übersicht findet sich zu Beginn des investorshub boards:
http://investorshub.advfn.com/Vanc-Pharmaceuticals-Inc-TSXV-…
auf iHub findet man finde ich generell, öfter, ganz gute Übersichten zu den Firmen
da sehen so einige Recherchen dagegen blass aus
Und mehr news ...:
http://www.stockhouse.com/companies/news/v.nph/vanc-pharmace…
"VANC Pharmaceuticals Announces Low Cost Alternative Approval of 14 Products From British Columbia Ministry of Health
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 24, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has received confirmation from the British Columbia (BC) Ministry of Health approving 14 of the Company's generic molecules under the Low Cost Alternative (LCA) program. The approval of these molecules makes them eligible for listing on British Columbia's provincial formulary and for reimbursement through Pharmacare. Pharmacare is the Province's coverage plan that assists residents with the cost of eligible prescription drugs and certain medical supplies.
"We are excited to have received LOA approval from the BC Ministry of Health as it signifies an important milestone in our evolution as a Company - we can now provide residents of BC with safety, quality and affordability when it comes to these 14 molecules," said Arun Nayyar, CEO of VANC. "We will continue to work with the Ministry of Health to gain approval of additional molecules during Q1-2015."
Table 1.0 provides a listing of the 14 approved products.
Molecule Name Presentations Brand
Reference
1 VAN-Rizatriptan 5 MG Tab Maxalt™
2 VAN-Amlodipine 5 MG and 10 MG Tab Norvasc™
3 VAN-Losartan 25 MG, 50 MG and 100 MG Tab Cozaar™
4 VAN-Losartan-HCTZ 50+12.5 MG and 100+25 MG Tab Hyzaar™
5 VAN-Levetiracetam 250 MG, 500 MG and 750 MG Tab Keppra™
6 VAN-Gabapentin Tab 600 MG and 800 MG Tab Neurontin™
7 VAN-Omeperazole 20 MG DR Tab Losec™
8 VAN-Finasteride 5 MG Tab Proscar™
9 VAN-Olanzapine 2.5 MG, 5 MG, 7.5 MG, 10 MG and 15 MG Tab Zyprexa™
10 VAN-Sertraline cap 25 MG, 50 MG and 100 MG Cap Zoloft™
11 VAN-Pantoprazole 40 MG Tab Pantoloc™
12 VAN-Gabapentin Cap 100 MG, 300 MG and 400 MG Cap Neurontin™
13 VAN-Ciprofloxacin 250 MG, 500 MG and 750 MG Tab Cipro™
14 VAN-Sildenafil 25 MG, 50 MG and 100 MG Tab Viagra™
About Low Cost Alternative (LCA) Program
The British Columbia Ministry of Health established the Low Cost Alternative (LCA) program under the Drug Price Regulation to ensure the best value is obtained for expenditures on multi-source drugs. The program works by limiting PharmaCare reimbursements for drug products subject to an LCA price.
For more information please visit: http://www.health.gov.bc.ca/pharmacare/
On behalf of:
VANC Pharmaceuticals Inc.
Arun Nayyar, President and CEO
..."
http://www.stockhouse.com/companies/news/v.nph/vanc-pharmace…
"VANC Pharmaceuticals Announces Low Cost Alternative Approval of 14 Products From British Columbia Ministry of Health
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 24, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has received confirmation from the British Columbia (BC) Ministry of Health approving 14 of the Company's generic molecules under the Low Cost Alternative (LCA) program. The approval of these molecules makes them eligible for listing on British Columbia's provincial formulary and for reimbursement through Pharmacare. Pharmacare is the Province's coverage plan that assists residents with the cost of eligible prescription drugs and certain medical supplies.
"We are excited to have received LOA approval from the BC Ministry of Health as it signifies an important milestone in our evolution as a Company - we can now provide residents of BC with safety, quality and affordability when it comes to these 14 molecules," said Arun Nayyar, CEO of VANC. "We will continue to work with the Ministry of Health to gain approval of additional molecules during Q1-2015."
Table 1.0 provides a listing of the 14 approved products.
Molecule Name Presentations Brand
Reference
1 VAN-Rizatriptan 5 MG Tab Maxalt™
2 VAN-Amlodipine 5 MG and 10 MG Tab Norvasc™
3 VAN-Losartan 25 MG, 50 MG and 100 MG Tab Cozaar™
4 VAN-Losartan-HCTZ 50+12.5 MG and 100+25 MG Tab Hyzaar™
5 VAN-Levetiracetam 250 MG, 500 MG and 750 MG Tab Keppra™
6 VAN-Gabapentin Tab 600 MG and 800 MG Tab Neurontin™
7 VAN-Omeperazole 20 MG DR Tab Losec™
8 VAN-Finasteride 5 MG Tab Proscar™
9 VAN-Olanzapine 2.5 MG, 5 MG, 7.5 MG, 10 MG and 15 MG Tab Zyprexa™
10 VAN-Sertraline cap 25 MG, 50 MG and 100 MG Cap Zoloft™
11 VAN-Pantoprazole 40 MG Tab Pantoloc™
12 VAN-Gabapentin Cap 100 MG, 300 MG and 400 MG Cap Neurontin™
13 VAN-Ciprofloxacin 250 MG, 500 MG and 750 MG Tab Cipro™
14 VAN-Sildenafil 25 MG, 50 MG and 100 MG Tab Viagra™
About Low Cost Alternative (LCA) Program
The British Columbia Ministry of Health established the Low Cost Alternative (LCA) program under the Drug Price Regulation to ensure the best value is obtained for expenditures on multi-source drugs. The program works by limiting PharmaCare reimbursements for drug products subject to an LCA price.
For more information please visit: http://www.health.gov.bc.ca/pharmacare/
On behalf of:
VANC Pharmaceuticals Inc.
Arun Nayyar, President and CEO
..."
Neues ATH !
Gruß, praesens
Gruß, praesens
Die TSX-V handelt zwar noch 80 min. - aber ich sage trotzdem schon mal: SK neues ATH !! 
Gruß, praesens
Gruß, praesens
Es ist zwar erst 17.35 Uhr, aber ich halte es für eine sichere Wette zu sagen: SK = neues ATH ...
Gruß, praesens
Gruß, praesens
Info.
2 days ago CXR bought Covis for $1.2 Billion. Covis had 18 generic branded products
''The Covis drug portfolio being acquired consists of 18 branded and authorized generic products with stable revenue, strong margins and free cash flow. The distinctive product portfolio includes branded pharmaceuticals, injectables and authorized generics that address life threatening and other serious medical conditions in various therapeutic areas including cardiovascular, central nervous system, oncology and acute care markets.''
Source
NPH has 49 products..(with 45 million shares out you do the math...)
CURRENT SATUS
Cross-referencing agreement – 30 products from globally reputed generic companies
Drug establishment license • Received in December 2014
Regulatory approval from Health Canada
• Submitted ANDS application for 33 products and in process of submission for remaining products
• Received 67 DINs
• Remaining 16 Products to be filed in Q1-2015 with Health Canada
SOURCE
Vanc Pharmaceuticals Inc. has signed a letter of intent with a multichain pharmacy based in Western Canada to become a preferred supplier of generic drugs and over-the-counter products.
SOURCE
Vanc Pharmaceuticals Inc. has received confirmation from the B.C. Ministry of Health approving 14 of the company's generic molecules under the Low Cost Alternative program.
The approval of these molecules makes them eligible for listing on British Columbia's provincial formulary and for reimbursement through Pharmacare. Pharmacare is the province's coverage plan that assists residents with the cost of eligible prescription drugs and certain medical supplies.
"We are excited to have received LOA approval from the B.C. Ministry of Health as it signifies an important milestone in our evolution as a company -- we can now provide residents of B.C. with safety, quality and affordability when it comes to these 14 molecules," said Arun Nayyar, chief executive officer of Vanc. "We will continue to work with the Ministry of Health to gain approval of additional molecules during Q1 2015."
source
Next Steps
Ordering – Purchase orders placed for 30 products
Packaging and Artwork – Ready for 30 products and in process of gaining approvals from manufacturers Manufacturing
– Q1-2015 Provincial Listing
– Applied for all products Sales and Marketing
– Expand sales and marketing team Q2-2015
QC – testing method transfers are in progress and agreement in place with an Ontario based testing lab
2 days ago CXR bought Covis for $1.2 Billion. Covis had 18 generic branded products
''The Covis drug portfolio being acquired consists of 18 branded and authorized generic products with stable revenue, strong margins and free cash flow. The distinctive product portfolio includes branded pharmaceuticals, injectables and authorized generics that address life threatening and other serious medical conditions in various therapeutic areas including cardiovascular, central nervous system, oncology and acute care markets.''
Source
NPH has 49 products..(with 45 million shares out you do the math...)
CURRENT SATUS
Cross-referencing agreement – 30 products from globally reputed generic companies
Drug establishment license • Received in December 2014
Regulatory approval from Health Canada
• Submitted ANDS application for 33 products and in process of submission for remaining products
• Received 67 DINs
• Remaining 16 Products to be filed in Q1-2015 with Health Canada
SOURCE
Vanc Pharmaceuticals Inc. has signed a letter of intent with a multichain pharmacy based in Western Canada to become a preferred supplier of generic drugs and over-the-counter products.
SOURCE
Vanc Pharmaceuticals Inc. has received confirmation from the B.C. Ministry of Health approving 14 of the company's generic molecules under the Low Cost Alternative program.
The approval of these molecules makes them eligible for listing on British Columbia's provincial formulary and for reimbursement through Pharmacare. Pharmacare is the province's coverage plan that assists residents with the cost of eligible prescription drugs and certain medical supplies.
"We are excited to have received LOA approval from the B.C. Ministry of Health as it signifies an important milestone in our evolution as a company -- we can now provide residents of B.C. with safety, quality and affordability when it comes to these 14 molecules," said Arun Nayyar, chief executive officer of Vanc. "We will continue to work with the Ministry of Health to gain approval of additional molecules during Q1 2015."
source
Next Steps
Ordering – Purchase orders placed for 30 products
Packaging and Artwork – Ready for 30 products and in process of gaining approvals from manufacturers Manufacturing
– Q1-2015 Provincial Listing
– Applied for all products Sales and Marketing
– Expand sales and marketing team Q2-2015
QC – testing method transfers are in progress and agreement in place with an Ontario based testing lab
http://www.stockhouse.com/news/press-releases/2015/03/12/van…
Corporate Update and Announces $2,000,000 in Proceeds from Warrant Exercises
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 12, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that the Company has received $2,000,000 in proceeds from the exercise of warrants.
"This injection of capital will assist us in two key areas of our Company as it puts us in a position to ramp up our Sales and Marketing team and allows for additional product acquisitions," said Arun Nayyar, CEO of Vanc. "We expect to begin shipping in Q2-2015 and have spent considerable time reviewing several product acquisitions that fit into our existing portfolio of generics and OTC products."
The Company expects initial inventory for 30 generic molecules to be delivered in early Q2-2015 and will commence manufacturing on the OTC products in Q2-2015 as well.
There are no material changes to report at this time. Additional updates on will be provided as they become available.
On behalf of:
VANC Pharmaceuticals Inc.
..."
Corporate Update and Announces $2,000,000 in Proceeds from Warrant Exercises
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 12, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that the Company has received $2,000,000 in proceeds from the exercise of warrants.
"This injection of capital will assist us in two key areas of our Company as it puts us in a position to ramp up our Sales and Marketing team and allows for additional product acquisitions," said Arun Nayyar, CEO of Vanc. "We expect to begin shipping in Q2-2015 and have spent considerable time reviewing several product acquisitions that fit into our existing portfolio of generics and OTC products."
The Company expects initial inventory for 30 generic molecules to be delivered in early Q2-2015 and will commence manufacturing on the OTC products in Q2-2015 as well.
There are no material changes to report at this time. Additional updates on will be provided as they become available.
On behalf of:
VANC Pharmaceuticals Inc.
..."
Info.
VOLUME = 94,191,709 SHARES TRADED FROM 02/19 TO 03/13/2015
IN 3 WEEKS ...
SHARES /OUT = 45,224,406 SHARES
SHARES TRADED = 94,191,709 .... IT'S THE + DOUBLE ...
WATCH THE NEXT WEEK VOLUME ... IF THE NEWS COMING ...
Read more at http://www.stockhouse.com/companies/bullboard/v.nph/vanc-pha…
Kann jetzt auch in Stuttgart gehandelt werden.
VOLUME = 94,191,709 SHARES TRADED FROM 02/19 TO 03/13/2015
IN 3 WEEKS ...
SHARES /OUT = 45,224,406 SHARES
SHARES TRADED = 94,191,709 .... IT'S THE + DOUBLE ...
WATCH THE NEXT WEEK VOLUME ... IF THE NEWS COMING ...
Read more at http://www.stockhouse.com/companies/bullboard/v.nph/vanc-pha…
Kann jetzt auch in Stuttgart gehandelt werden.
Antwort auf Beitrag Nr.: 49.328.228 von Montekaolino am 14.03.15 11:36:20Kann zwar in Stuttgart gehandelt werden - so wie ich gesehen habe die ganze vorherige Woche schon - jedoch ohne jeglichen Umsatz.
Antwort auf Beitrag Nr.: 49.328.681 von peikler am 14.03.15 12:58:40
Richtig.
Die Aktie ist hier nur wenigen bekannt aber ich sehe hier länger ein gutes invest.
Bin bei NSP,NPH Canada und EAPH USA mal dabei.
Richtig.
Die Aktie ist hier nur wenigen bekannt aber ich sehe hier länger ein gutes invest.
Bin bei NSP,NPH Canada und EAPH USA mal dabei.
Antwort auf Beitrag Nr.: 49.328.954 von Montekaolino am 14.03.15 14:06:31Hi,
bei NSP bin ich auch dicke drin.
bei NSP bin ich auch dicke drin.
Antwort auf Beitrag Nr.: 49.328.954 von Montekaolino am 14.03.15 14:06:31EAPH ist das Easton?
Da wurde in der Tat noch das gap zwischen 44 und 46 cent geschlossen. Ein Traum für einen trader. Blöd daß ich Keiner bin ... 
Gruß, praesens
Gruß, praesens
Antwort auf Beitrag Nr.: 49.329.068 von peikler am 14.03.15 14:45:33
Easton Pharmaceuticals USOTC:EAPH
Easton Pharmaceuticals USOTC:EAPH
E N D L I C H !!
Halted !:
http://www.stockhouse.com/news/press-releases/2015/05/01/iir…
"IIROC Trading Halt - NPH
V.NPH | 15 minutes ago
VANCOUVER, May 1, 2015 /CNW/ - The following issues have been halted by IIROC:
Company: Vanc Pharmaceuticals Inc.
TSX-Venture Symbol: NPH
Reason: At the Request of the Company Pending News
..."
Halted !:
http://www.stockhouse.com/news/press-releases/2015/05/01/iir…
"IIROC Trading Halt - NPH
V.NPH | 15 minutes ago
VANCOUVER, May 1, 2015 /CNW/ - The following issues have been halted by IIROC:
Company: Vanc Pharmaceuticals Inc.
TSX-Venture Symbol: NPH
Reason: At the Request of the Company Pending News
..."
Antwort auf Beitrag Nr.: 49.690.089 von praesens am 01.05.15 15:28:24
Lassen wir uns mal überraschen was da kommt.
Lassen wir uns mal überraschen was da kommt.
Gibt es mehr Informationen?
Bisher hat diese Aktie wenige wahrgenommen...
Bisher hat diese Aktie wenige wahrgenommen...
Wann soll der Handel wieder aufgenommen werden?
Und dafür ein trading halt ?
Na vielleicht kommt ja noch eine 2. news nach ...
http://www.stockhouse.com/news/press-releases/2015/05/04/van…
VANC Pharmaceuticals Announces Health Canada Approval for 5 New Generic Molecules and Provides Commercialization Update
V.NPH | 26 minutes ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 4, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company") is pleased to announce that it has received Drug Identification Numbers (DIN) from Health Canada for 5 new generic molecules as an initial notice of consent for new drug submissions. These 5 molecules will comprise of 14 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy.
VANC will start manufacturing of these products once Notice of Compliance (NOC) is received from Health Canada, which is anticipated in the next few weeks. The NOC from Health Canada provides the authorization for VANC to market and sell the generic molecules in Canada. "We are excited to continue growing our portfolio of generic drugs as we work towards commercialization this quarter," said Arun Nayyar, CEO of VANC. "We will continue to expand our portfolio with niche market molecules that are applicable to the Canadian market."
Table 1.0 provides details on each of the molecules.
Molecule Name Presentations Brand Reference
1 VAN-Citalopram 10 MG, 20 MG and 40 MG Tab Celexa™
2 VAN- Olanzapine ODT 5 MG, 10 MG, 15 MG and 20 MG Tab Zyprexa Zydis™
3 VAN- Ramipril Cap 1.25 MG, 2.5 MG, 5 MG, 10 MG and 15 MG Tab Altace™
4 VAN- Zolmitriptan 2.5 MG Tab Zomig™
5 VAN- Zolmitriptan ODT 2.5 MG Tab Zomig Rapimelt™
Table 1.0
Further to the press release of January 14, 2015 the Company is pleased to report that it has begun taking delivery of initial generic drug inventory from purchase orders placed with manufacturers earlier this year. "We are happy to advise that our product inventory build-up is on schedule and we will be ready to ship some of these products to customers towards the end of Q2-2015," said Nayyar.
As a part of the sales and marketing strategy the Company has hired a Manager of Sales and Marketing, who has over 15 years of experience as a Pharmacist with a multi-chain pharmacy. The Company anticipates ramping up the sales team with additional hiring's during Q3-2015.
On behalf of:
VANC Pharmaceuticals Inc.
Aman Parmar, CFO and Director
..."
Na vielleicht kommt ja noch eine 2. news nach ...
http://www.stockhouse.com/news/press-releases/2015/05/04/van…
VANC Pharmaceuticals Announces Health Canada Approval for 5 New Generic Molecules and Provides Commercialization Update
V.NPH | 26 minutes ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 4, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company") is pleased to announce that it has received Drug Identification Numbers (DIN) from Health Canada for 5 new generic molecules as an initial notice of consent for new drug submissions. These 5 molecules will comprise of 14 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy.
VANC will start manufacturing of these products once Notice of Compliance (NOC) is received from Health Canada, which is anticipated in the next few weeks. The NOC from Health Canada provides the authorization for VANC to market and sell the generic molecules in Canada. "We are excited to continue growing our portfolio of generic drugs as we work towards commercialization this quarter," said Arun Nayyar, CEO of VANC. "We will continue to expand our portfolio with niche market molecules that are applicable to the Canadian market."
Table 1.0 provides details on each of the molecules.
Molecule Name Presentations Brand Reference
1 VAN-Citalopram 10 MG, 20 MG and 40 MG Tab Celexa™
2 VAN- Olanzapine ODT 5 MG, 10 MG, 15 MG and 20 MG Tab Zyprexa Zydis™
3 VAN- Ramipril Cap 1.25 MG, 2.5 MG, 5 MG, 10 MG and 15 MG Tab Altace™
4 VAN- Zolmitriptan 2.5 MG Tab Zomig™
5 VAN- Zolmitriptan ODT 2.5 MG Tab Zomig Rapimelt™
Table 1.0
Further to the press release of January 14, 2015 the Company is pleased to report that it has begun taking delivery of initial generic drug inventory from purchase orders placed with manufacturers earlier this year. "We are happy to advise that our product inventory build-up is on schedule and we will be ready to ship some of these products to customers towards the end of Q2-2015," said Nayyar.
As a part of the sales and marketing strategy the Company has hired a Manager of Sales and Marketing, who has over 15 years of experience as a Pharmacist with a multi-chain pharmacy. The Company anticipates ramping up the sales team with additional hiring's during Q3-2015.
On behalf of:
VANC Pharmaceuticals Inc.
Aman Parmar, CFO and Director
..."
Antwort auf Beitrag Nr.: 49.703.304 von praesens am 04.05.15 14:30:52Gute news, ja, (5 more approvals / erste Lieferungen vom Hersteller eingetroffen / Auslieferung an die Kunden gegen Ende Q2 / Ausbau des Verkaufsteams) aber nichts Neues bzw. nichts was nicht zu erwarten gewesen wäre.
http://www.stockhouse.com/news/press-releases/2015/05/04/iir…
IIROC Trading Resumption - NPH
V.NPH | 46 minutes ago
VANCOUVER, May 4, 2015 /CNW/ - Trading resumes in:
Company: Vanc Pharmaceuticals Inc.
TSX-Venture Symbol: NPH
Resumption (ET): 9:00
..."
IIROC Trading Resumption - NPH
V.NPH | 46 minutes ago
VANCOUVER, May 4, 2015 /CNW/ - Trading resumes in:
Company: Vanc Pharmaceuticals Inc.
TSX-Venture Symbol: NPH
Resumption (ET): 9:00
..."
News:
http://www.stockhouse.com/news/press-releases/2015/06/05/van…
"VANC Pharmaceuticals Announces Appointment of Mr. Bob Rai to its Board of Directors
NUVPF, V.NPH | 7 hours ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 5, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce that Mr.Bob Rai has been appointed to the Company's Board of Directors effective immediately. Mr. Rai is a pharmacist with over 15 years of experience and is partner in a chain of The Medicine Shoppe Pharmacy (www.pharmacybc.com).
"We are excited to have someone with Mr. Rai's industry experience, track record as an entrepreneur and global pedigree join our board. We welcome him to our growing team and eagerly await his input on the strategic direction of our Company," said Arun Nayyar, CEO of VANC. "As we begin the commercialization of our product portfolio it is crucial that our team be optimized and Mr. Rai's direct experience in the Canadian retail and institutional pharmacy business is going to be an immediate value add and impactful addition for the Company."
Mr. Rai is a graduate of the University of British Columbia with Bachelor of Science Degrees in Biochemistry and Pharmaceutical Science. In addition to operating a chain of The Medicine Shoppe Pharmacies in Greater Vancouver for the past 15 years, he has had several successful entrepreneurial and charitable endeavors. In 1998 Mr. Rai and his partners pioneered and revolutionized the online pharmacy business to the United States. The online sales and distribution of prescription medicines saw unprecedented industry growth and as other operators followed suit, the unique business concept became a billion dollar industry across Canada.
Mr. Rai is also Chairman and CEO of Canada Pacific Global Pharmaceuticals and Chairman of its subsidiary, PharmaCanada Inc. (www.earlycancerdetect.com). He has served as President of the Philippines Canada Trade Council (PCTC) from 2006-2007 and held the position of Vice-President from 2004-2006. As President of PCTC, he led a successful Trade Mission to Manila with endorsements from His Excellency Canadian Prime Minister Stephen Harper, Honorable Premier Gordon Campbell of British Columbia and Minister of International Trade and Industry of Canada David Emerson.
In 2013 Mr. Rai was the recipient of the Queen's Diamond Jubilee Medal for his over 18 years of community and volunteer work. His charitable and community volunteer activities include: Alumni UBC Advisory Council representing the Faculty of Pharmaceutical Science, Director of Tapestry Foundation for Health Care, Rotary Club of Vancouver Fraserview and cabinet member of "A Night of Miracles" for BC Children's Hospital.
"I am impressed with how far VANC has come as a startup in a highly competitive industry and commend the existing team for building a product portfolio, registering it with Health Canada and rolling it out commercially in such a cost and time efficient manner. I look forward to working with the team and helping them with governance, technology, product acquisition and accelerating sales," said Mr. Bob Rai.
The Company has also set aside 400,000 incentive stock options at $0.45 for a period of five years and 800,000 incentive stock options at $0.55 for a period of two years to Directors, Officers and Consultants.
..."
http://www.stockhouse.com/news/press-releases/2015/06/05/van…
"VANC Pharmaceuticals Announces Appointment of Mr. Bob Rai to its Board of Directors
NUVPF, V.NPH | 7 hours ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 5, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce that Mr.Bob Rai has been appointed to the Company's Board of Directors effective immediately. Mr. Rai is a pharmacist with over 15 years of experience and is partner in a chain of The Medicine Shoppe Pharmacy (www.pharmacybc.com).
"We are excited to have someone with Mr. Rai's industry experience, track record as an entrepreneur and global pedigree join our board. We welcome him to our growing team and eagerly await his input on the strategic direction of our Company," said Arun Nayyar, CEO of VANC. "As we begin the commercialization of our product portfolio it is crucial that our team be optimized and Mr. Rai's direct experience in the Canadian retail and institutional pharmacy business is going to be an immediate value add and impactful addition for the Company."
Mr. Rai is a graduate of the University of British Columbia with Bachelor of Science Degrees in Biochemistry and Pharmaceutical Science. In addition to operating a chain of The Medicine Shoppe Pharmacies in Greater Vancouver for the past 15 years, he has had several successful entrepreneurial and charitable endeavors. In 1998 Mr. Rai and his partners pioneered and revolutionized the online pharmacy business to the United States. The online sales and distribution of prescription medicines saw unprecedented industry growth and as other operators followed suit, the unique business concept became a billion dollar industry across Canada.
Mr. Rai is also Chairman and CEO of Canada Pacific Global Pharmaceuticals and Chairman of its subsidiary, PharmaCanada Inc. (www.earlycancerdetect.com). He has served as President of the Philippines Canada Trade Council (PCTC) from 2006-2007 and held the position of Vice-President from 2004-2006. As President of PCTC, he led a successful Trade Mission to Manila with endorsements from His Excellency Canadian Prime Minister Stephen Harper, Honorable Premier Gordon Campbell of British Columbia and Minister of International Trade and Industry of Canada David Emerson.
In 2013 Mr. Rai was the recipient of the Queen's Diamond Jubilee Medal for his over 18 years of community and volunteer work. His charitable and community volunteer activities include: Alumni UBC Advisory Council representing the Faculty of Pharmaceutical Science, Director of Tapestry Foundation for Health Care, Rotary Club of Vancouver Fraserview and cabinet member of "A Night of Miracles" for BC Children's Hospital.
"I am impressed with how far VANC has come as a startup in a highly competitive industry and commend the existing team for building a product portfolio, registering it with Health Canada and rolling it out commercially in such a cost and time efficient manner. I look forward to working with the team and helping them with governance, technology, product acquisition and accelerating sales," said Mr. Bob Rai.
The Company has also set aside 400,000 incentive stock options at $0.45 for a period of five years and 800,000 incentive stock options at $0.55 for a period of two years to Directors, Officers and Consultants.
..."
Antwort auf Beitrag Nr.: 49.921.755 von praesens am 05.06.15 21:15:07http://www.medicineshoppe.com/about-us:
"About us
... The Medicine Shoppe pharmacy was established in 1968 ...
In 1995, Cardinal Health, acquired MSI...
About Medicine Shoppe International
Medicine Shoppe International, Inc. (MSI), a Cardinal Health Company, is distinguished for its commitment to providing expert, personalized health care. MSI is one of the largest franchisors of independent community pharmacies in the U.S. with over 500 Medicine Shoppe and Medicap Pharmacy** locations across the United States, and more than 200 international pharmacies ...
... About Cardinal Health, Inc.
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products and services to more than 100,000 locations each day and is also the industry-leading direct-to-home medical supplies distributor. The company is a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company operates the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #22 on the Fortune 500, Cardinal Health employs 34,000 people worldwide ..."
"About us
... The Medicine Shoppe pharmacy was established in 1968 ...
In 1995, Cardinal Health, acquired MSI...
About Medicine Shoppe International
Medicine Shoppe International, Inc. (MSI), a Cardinal Health Company, is distinguished for its commitment to providing expert, personalized health care. MSI is one of the largest franchisors of independent community pharmacies in the U.S. with over 500 Medicine Shoppe and Medicap Pharmacy** locations across the United States, and more than 200 international pharmacies ...
... About Cardinal Health, Inc.
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products and services to more than 100,000 locations each day and is also the industry-leading direct-to-home medical supplies distributor. The company is a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company operates the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #22 on the Fortune 500, Cardinal Health employs 34,000 people worldwide ..."
Antwort auf Beitrag Nr.: 49.921.785 von praesens am 05.06.15 21:20:44Aus einer news von 2012:
"About Medicine Shoppe Canada Inc.:
In Canada since 1991, The Medicine Shoppe franchise network of owner-operated pharmacies has grown to over 160 stores in nine provinces across Canada,"
Quelle: http://www.stockhouse.com/companies/bullboard/v.nph/vanc-pha…
"About Medicine Shoppe Canada Inc.:
In Canada since 1991, The Medicine Shoppe franchise network of owner-operated pharmacies has grown to over 160 stores in nine provinces across Canada,"
Quelle: http://www.stockhouse.com/companies/bullboard/v.nph/vanc-pha…
Neue Präsentation auf der website:
http://vancpharm.com/wp-content/uploads/2015/06/2015-06_Vanc…
Seite 9:
"... Commercialization commenced in Q2 2015 ..."
Gruß, praesens
http://vancpharm.com/wp-content/uploads/2015/06/2015-06_Vanc…
Seite 9:
"... Commercialization commenced in Q2 2015 ..."
Gruß, praesens
http://www.stockhouse.com/news/press-releases/2015/07/08/van…
"VANC Pharmaceuticals Commences Commercialization in British Columbia and Receives $1,095,728 in Proceeds From Warrant and Option Exercises
NUVPF, V.NPH | 1 hour ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 8, 2015) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commenced commercialization of its generic drug portfolio in British Columbia (BC) and has started shipping initial purchase orders to pharmacy customers.
"We are excited to have launched sales in our home province of BC and over the next two quarters we will work towards listing on other Provincial formularies which will open up additional markets in our roll-out strategy," said Arun Nayyar, CEO of VANC. "We look forward to ramping up sales in Q3-2015 and introducing additional products to our customers."
Further, to the Company's press release from March 12, 2015 the Company has received an additional $1,095,728 from warrant and option exercises, bringing the total proceeds from warrant and option exercises during the first two quarters of the calendar year to $3,095,728.
On behalf of:
VANC Pharmaceuticals Inc.
Aman Parmar, CFO and Director
..."
"VANC Pharmaceuticals Commences Commercialization in British Columbia and Receives $1,095,728 in Proceeds From Warrant and Option Exercises
NUVPF, V.NPH | 1 hour ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 8, 2015) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commenced commercialization of its generic drug portfolio in British Columbia (BC) and has started shipping initial purchase orders to pharmacy customers.
"We are excited to have launched sales in our home province of BC and over the next two quarters we will work towards listing on other Provincial formularies which will open up additional markets in our roll-out strategy," said Arun Nayyar, CEO of VANC. "We look forward to ramping up sales in Q3-2015 and introducing additional products to our customers."
Further, to the Company's press release from March 12, 2015 the Company has received an additional $1,095,728 from warrant and option exercises, bringing the total proceeds from warrant and option exercises during the first two quarters of the calendar year to $3,095,728.
On behalf of:
VANC Pharmaceuticals Inc.
Aman Parmar, CFO and Director
..."
Honey in the pot
Ah, gut, dafür war ich die ganze Zeit zu faul - Dank an user drliquid auf stockhouse:
"Also, here's an updated Provincial Formulary Recap.
BC - 38
AB - 41 (32 approved by Sept 1)
SK - 23
MB - 3 (I believe the MB formulary is lagging behind due to issuing quarterly updates)
ON - 27
QC - (8 as of October 1... also look for more to be added on the November 16 update)"
"Also, here's an updated Provincial Formulary Recap.
BC - 38
AB - 41 (32 approved by Sept 1)
SK - 23
MB - 3 (I believe the MB formulary is lagging behind due to issuing quarterly updates)
ON - 27
QC - (8 as of October 1... also look for more to be added on the November 16 update)"
News von Dienstag.
Ohne klare Zahlen etc. wie manche erwartet hatten, daher eine leichte Enttäuschung, die sich auch im Kurs niederschlägt:
http://www.stockhouse.com/news/press-releases/2015/09/22/van…
"Vanc Pharmaceuticals Provides Corporate Update
NUVPF, V.NPH | 1 day ago
- Shipping of pharmacy orders commenced in late Q2-2015 - Roll-out into additional Canadian jurisdictions to commence in Q4-2015 - Additional generic and OTC products being reviewed for portfolio
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 22, 2015) - Vanc Pharmaceuticals Inc. ("Vanc" or the "Company")(TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to provide a corporate update on the activities and progress of the Company over the past three months.
"The key areas in which we have made progress thus far are the commercialization of our generic drug molecules, shipment of our first molecule during the final week of Q2-2015 and the strengthening of our balance sheet with over $3,000,000 in cash injections from warrant exercises during the previous two quarters. As of early September we currently have a portfolio of 12 molecules ready for sale in British Columbia (BC) and many pharmacies have placed orders," said Arun Nayyar, CEO of Vanc.
The Company has ramped up sales efforts in BC given the size of the portfolio and will be commencing commercialization in additional Canadian jurisdictions during Q4-2015. Additional updates on Provincial formulary listings and the roll-out in other Provinces will be provided over the coming months.
The Company has spent considerable time reviewing potential additions to its generic and OTC (over-the-counter) portfolio and is in negotiations to potentially in-license both niche generic molecules and novel OTC products.
On behalf of:
Vanc Pharmaceuticals Inc.
Aman Parmar, CFO and Director
..."
Ohne klare Zahlen etc. wie manche erwartet hatten, daher eine leichte Enttäuschung, die sich auch im Kurs niederschlägt:
http://www.stockhouse.com/news/press-releases/2015/09/22/van…
"Vanc Pharmaceuticals Provides Corporate Update
NUVPF, V.NPH | 1 day ago
- Shipping of pharmacy orders commenced in late Q2-2015 - Roll-out into additional Canadian jurisdictions to commence in Q4-2015 - Additional generic and OTC products being reviewed for portfolio
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 22, 2015) - Vanc Pharmaceuticals Inc. ("Vanc" or the "Company")(TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to provide a corporate update on the activities and progress of the Company over the past three months.
"The key areas in which we have made progress thus far are the commercialization of our generic drug molecules, shipment of our first molecule during the final week of Q2-2015 and the strengthening of our balance sheet with over $3,000,000 in cash injections from warrant exercises during the previous two quarters. As of early September we currently have a portfolio of 12 molecules ready for sale in British Columbia (BC) and many pharmacies have placed orders," said Arun Nayyar, CEO of Vanc.
The Company has ramped up sales efforts in BC given the size of the portfolio and will be commencing commercialization in additional Canadian jurisdictions during Q4-2015. Additional updates on Provincial formulary listings and the roll-out in other Provinces will be provided over the coming months.
The Company has spent considerable time reviewing potential additions to its generic and OTC (over-the-counter) portfolio and is in negotiations to potentially in-license both niche generic molecules and novel OTC products.
On behalf of:
Vanc Pharmaceuticals Inc.
Aman Parmar, CFO and Director
..."
http://www.stockhouse.com/news/press-releases/2015/10/07/van…
"VANC Pharmaceuticals Announces Listing of Products on Six Provincial Formularies in Canada
NUVPF, V.NPH | 3 hours ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 7, 2015) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce that it has listed multiple products in Provincial formularies of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec.
The Provincial formularies list drugs for which particular public or private health plans will pay all or part of the cost and the circumstances in which the coverage is available. Each Province maintains the formulary autonomously and decides regarding which drugs and which individuals are covered.
"The listing on Provincial formularies across Canada is a major step in commercializing our generics portfolio across Canada. We have now registered a minimum of 7 molecules and 20 stock keeping units (the "SKUs") in six Provinces. The next step will be to expand our sales force through the hiring of reps in each of the Provinces," said Arun Nayyar, CEO of VANC.
Table 1.0 lists the number of molecules listed in each provincial formulary. The drugs having no coverage from provincial health care plans are considered to be non-benefit drugs.
Province Listed Non-Benefit Total Number
of Molecules
British Columbia 14 4 18
Alberta 15 7 22
Saskatchewan 14 4 18
Manitoba 1 1 2
Ontario 14 - 14
Quebec 8 1 9
Table 1.0
A full listing of the molecules and SKUs listed in each of the provinces can be seen at http://vancpharm.com/products/.
The Company will provide updates on commercialization and additional product listings across Canada during Q4-2015.
On behalf of:
VANC Pharmaceuticals Inc.
Aman Parmar, CFO and Director
..."
"VANC Pharmaceuticals Announces Listing of Products on Six Provincial Formularies in Canada
NUVPF, V.NPH | 3 hours ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 7, 2015) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce that it has listed multiple products in Provincial formularies of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec.
The Provincial formularies list drugs for which particular public or private health plans will pay all or part of the cost and the circumstances in which the coverage is available. Each Province maintains the formulary autonomously and decides regarding which drugs and which individuals are covered.
"The listing on Provincial formularies across Canada is a major step in commercializing our generics portfolio across Canada. We have now registered a minimum of 7 molecules and 20 stock keeping units (the "SKUs") in six Provinces. The next step will be to expand our sales force through the hiring of reps in each of the Provinces," said Arun Nayyar, CEO of VANC.
Table 1.0 lists the number of molecules listed in each provincial formulary. The drugs having no coverage from provincial health care plans are considered to be non-benefit drugs.
Province Listed Non-Benefit Total Number
of Molecules
British Columbia 14 4 18
Alberta 15 7 22
Saskatchewan 14 4 18
Manitoba 1 1 2
Ontario 14 - 14
Quebec 8 1 9
Table 1.0
A full listing of the molecules and SKUs listed in each of the provinces can be seen at http://vancpharm.com/products/.
The Company will provide updates on commercialization and additional product listings across Canada during Q4-2015.
On behalf of:
VANC Pharmaceuticals Inc.
Aman Parmar, CFO and Director
..."
Quarterly für fiscal Q1 2016 (Juli/Aug/Sept ´15) ist raus auf sedar.com.
Das annual zum 30.06. übrigens auch bereits seit einigen Wochen.
Gruß, praesens
Das annual zum 30.06. übrigens auch bereits seit einigen Wochen.
Gruß, praesens
http://www.stockhouse.com/news/press-releases/2015/12/07/van…
"Vanc Pharmaceuticals Launches First OTC Product in British Columbia
NUVPF, V.NPH | 20 hours ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 7, 2015) - Vanc Pharmaceuticals Inc. ("Vanc" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commercialized its first OTC products in British Columbia: Cortivera™ and Cortivera Plus™ (Natural Product Number (NPN): 80037898) for a wide range of minor skin irritations, allergic reactions and eczema.
Both products are formulated with aloe vera and Cortivera™ contains 0.5% hydrocortisone and Cortivera Plus™ contains 1% hydrocortisone. Both are available in cream and ointment form in order to meet the specific needs of patients. The combination of aloe vera and hydrocortisone offers therapeutic benefits for skin irritations such as minor burns, allergic itch, insect bite itch, sun burn itch, eczema in addition to acting as an anti-inflammatory.
"We are excited to have launched the first product from our OTC portfolio and are confident in its ability to compete with the leading products in the category," said Arun Nayyar, CEO of Vanc. "In addition to our generic drug business which is seeing sales ramp up we have received positive feedback from pharmacy customers on Cortivera™ and Cortivera Plus™."
On behalf of:
Vanc Pharmaceuticals Inc.
Arun Nayyar, CEO
..."
"Vanc Pharmaceuticals Launches First OTC Product in British Columbia
NUVPF, V.NPH | 20 hours ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 7, 2015) - Vanc Pharmaceuticals Inc. ("Vanc" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commercialized its first OTC products in British Columbia: Cortivera™ and Cortivera Plus™ (Natural Product Number (NPN): 80037898) for a wide range of minor skin irritations, allergic reactions and eczema.
Both products are formulated with aloe vera and Cortivera™ contains 0.5% hydrocortisone and Cortivera Plus™ contains 1% hydrocortisone. Both are available in cream and ointment form in order to meet the specific needs of patients. The combination of aloe vera and hydrocortisone offers therapeutic benefits for skin irritations such as minor burns, allergic itch, insect bite itch, sun burn itch, eczema in addition to acting as an anti-inflammatory.
"We are excited to have launched the first product from our OTC portfolio and are confident in its ability to compete with the leading products in the category," said Arun Nayyar, CEO of Vanc. "In addition to our generic drug business which is seeing sales ramp up we have received positive feedback from pharmacy customers on Cortivera™ and Cortivera Plus™."
On behalf of:
Vanc Pharmaceuticals Inc.
Arun Nayyar, CEO
..."
Für das letzte quarterly hat Vanc ca. 6 Wochen gebraucht. Das wäre dann aktuell bis Mitte Februar. Spannend ...
Gruß, praesens
Gruß, praesens
http://www.stockhouse.com/news/press-releases/2016/01/21/van…
"VANC Pharmaceuticals Appointment of Mr. David Hall to Its Board of Directors
NUVPF, V.NPH | 29 minutes ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 21, 2016) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce the appointment of Mr. David M. Hall to VANC's Board of Directors.
Mr. Hall is currently Chairman of RepliCel Life Sciences and a consultant to the life sciences industry. Mr. Hall served as CEO and President of RepliCel Life Sciences (the "RepliCel") from 2012 through 2105. He has been instrumental in diversifying RepliCel's cell therapy programs from a single program focused on pattern baldness to three current clinical programs addressing chronic tendinosis and aging, sun damaged skin and pattern baldness as well as the development of a new dermal injector device for the delivery of cells, drugs, biologics and dermal fillers. Prior to RepliCel, Mr. Hall consulted to government, pharma industry, biotech, eHealth and NGO's for two years. For the prior 15 years, Mr. Hall was a business founder, CFO, CCO, Treasurer and Secretary of Angiotech Pharmaceuticals Inc.
Mr. Hall is a Past Chair and board member of Life Sciences BC and current director of Providence Health Care Research Institute. He is the author of Life Sciences BC's position papers for the Premier's Competition Council Report and Conversation on Health. Mr. Hall was also a member of the BC Task Force on PharmaCare and serves on the board of directors of the Advantage BC. Mr. Hall holds an Honours degree in Economics and an Honours degree in Finance from the University of Manitoba.
The Company also wishes to announce that it has granted an aggregate of 1,700,000 incentive stock options to the directors, officers and consultants of the Company, pursuant to the terms and conditions of the Company's stock option plan at $0.35 per share subject to regulatory regulations.
On behalf of VANC Pharmaceuticals Inc.
Eugene Beukman, Corporate Secretary
..."
"VANC Pharmaceuticals Appointment of Mr. David Hall to Its Board of Directors
NUVPF, V.NPH | 29 minutes ago
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 21, 2016) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce the appointment of Mr. David M. Hall to VANC's Board of Directors.
Mr. Hall is currently Chairman of RepliCel Life Sciences and a consultant to the life sciences industry. Mr. Hall served as CEO and President of RepliCel Life Sciences (the "RepliCel") from 2012 through 2105. He has been instrumental in diversifying RepliCel's cell therapy programs from a single program focused on pattern baldness to three current clinical programs addressing chronic tendinosis and aging, sun damaged skin and pattern baldness as well as the development of a new dermal injector device for the delivery of cells, drugs, biologics and dermal fillers. Prior to RepliCel, Mr. Hall consulted to government, pharma industry, biotech, eHealth and NGO's for two years. For the prior 15 years, Mr. Hall was a business founder, CFO, CCO, Treasurer and Secretary of Angiotech Pharmaceuticals Inc.
Mr. Hall is a Past Chair and board member of Life Sciences BC and current director of Providence Health Care Research Institute. He is the author of Life Sciences BC's position papers for the Premier's Competition Council Report and Conversation on Health. Mr. Hall was also a member of the BC Task Force on PharmaCare and serves on the board of directors of the Advantage BC. Mr. Hall holds an Honours degree in Economics and an Honours degree in Finance from the University of Manitoba.
The Company also wishes to announce that it has granted an aggregate of 1,700,000 incentive stock options to the directors, officers and consultants of the Company, pursuant to the terms and conditions of the Company's stock option plan at $0.35 per share subject to regulatory regulations.
On behalf of VANC Pharmaceuticals Inc.
Eugene Beukman, Corporate Secretary
..."
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -7,69 | |
| +2,38 | |
| -19,42 | |
| -4,60 | |
| +13,64 | |
| +0,75 | |
| -14,94 | |
| 0,00 | |
| +8,00 | |
| -3,65 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 221 | ||
| 106 | ||
| 94 | ||
| 64 | ||
| 50 | ||
| 41 | ||
| 36 | ||
| 36 | ||
| 34 | ||
| 25 |
